Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global TROP-2 Targeted Therapy Market Set to Reach USD 3.29 Billion by 2031 with an 8.6% CAGR

globenewswire.com
GILD Gilead Sciences is a key player in the TROP-2 targeted therapy market with its approved product Sacituzumab Govitecan (Trodelvy). The company is well-positioned to benefit from the projected market growth driven by increasing cancer prevalence and the adoption of ADCs. AZN AstraZeneca is a key player with its pipeline product Datopotamab Deruxtecan, a TROP-2 targeted therapy. The company is expected to benefit from the significant growth projected for the TROP-2 targeted therapy market, driven by advancements in ADCs and precision medicine. PFE Pfizer is mentioned as a key player in the TROP-2 targeted therapy market, focusing on ADC innovation and collaborations. While not having a specific TROP-2 therapy highlighted as a primary driver, its involvement in the broader oncology space and potential collaborations suggest a neutral to moderately positive outlook. MRK Merck & Co. is mentioned for its oncology portfolio and participation in combination trials with TROP-2 therapies. This indicates involvement in the growing field, but the article does not highlight a specific TROP-2 product as a primary growth driver for the company. BMY While not explicitly named in the 'Key players' section, Bristol Myers Squibb is a significant player in the oncology market and has been involved in TROP-2 research and development. Its broad oncology portfolio and potential for future involvement in this growing market suggest a neutral sentiment. BIIB Biogen is not explicitly mentioned in the article in relation to TROP-2 therapies. While it is a biotechnology company, its direct involvement in this specific market segment is not detailed, leading to an unknown strength and neutral sentiment based solely on this article. BNTX BioNTech SE is mentioned for its oncology pipeline and relevant immunotherapy combinations. Its involvement in combination therapies within the oncology space, which includes TROP-2 targeted therapies, suggests a neutral but potentially growing interest.

Global TROP-2 Targeted Therapy Market Set to Reach USD 3.29 Billion by 2031 with an 8.6% CAGR Dublin, July 03, 2026 (GLOBE NEWSWIRE) -- The "TROP-2 Targeted Therapy Market - Strategic Insights and Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

The global TROP-2 targeted therapy market is poised for remarkable growth, projected to reach USD 3.29 billion in 2031, up from USD 2.18 billion in 2026, at a CAGR of 8.6%. This significant expansion reflects an increasing focus by biotechnology and pharmaceutical firms on TROP-2, a key transmembrane glycoprotein prevalent in various epithelial cancers. The market covers a variety of innovative therapies, including antibody-drug conjugates (ADCs), monoclonal antibodies, bispecific antibodies, and targeted immunotherapies, aimed at improving cancer treatment effectiveness.

A major growth driver is the global rise in cancer cases, particularly those with high TROP-2 expression, such as breast cancer, non-small cell lung cancer, and pancreatic cancer. The demand for effective therapies that target cancer cells while sparing healthy tissues has surged, boosting clinical interest in TROP-2 therapies.

The growing emphasis on precision medicine and biomarker-driven oncology further supports market development. These strategies enable personalized treatment plans, increasing the therapeutic success of TROP-2 targeted therapies. Technological advancements in ADCs have revolutionized the landscape, providing enhanced precision and reduced toxicity compared to conventional chemotherapy.

TROP-2 therapies are also increasingly utilized in difficult-to-treat cancers, such as triple-negative breast cancer and metastatic urothelial carcinoma, due to their demonstrated ability to improve patient outcomes. Ongoing clinical research and heavy investment in novel therapeutic approaches continue to fuel market growth.

AI and computational biology are reshaping therapy development, aiding in genomic analysis, target identification, and trial optimization. Such technologies enhance precision oncology, offering tailored therapeutic solutions based on tumor biology.

Combination therapy strategies, involving immune checkpoint inhibitors or targeted molecules, are gaining traction. These combinations aim to enhance the anti-tumor response and overcome resistance.

The market faces challenges, such as high costs, regulatory hurdles, and potential toxicity. Nonetheless, the ongoing innovation in ADC technologies and precision medicine promises significant growth opportunities.

Regionally, North America leads the market, bolstered by advanced healthcare systems and biotechnology ecosystems, with the U.S. spearheading research and ADC commercialization. Europe is also significant due to precision oncology initiatives, while Asia-Pacific is set for rapid expansion due to rising cancer prevalence and healthcare infrastructure advancements.

Key Market Drivers

Market Challenges

Technology & Segment Insights

The market is segmented by therapy type, cancer indication, technology, and geography. ADCs currently dominate due to strong clinical efficacy and regulatory approvals.

Competitive Landscape

Key players include Gilead Sciences, AstraZeneca, Pfizer, and others, focusing on ADC innovation, AI-powered drug discovery, and strategic collaborations.

Conclusion

The TROP-2 targeted therapy market is set for robust growth driven by cancer prevalence, precision oncology adoption, and continuous technological advancements, promising substantial long-term opportunities despite existing challenges.

Key Topics Covered:

1. Executive Summary

1.1 Market Overview

1.2 Key Findings

1.3 Market Size & Forecast Snapshot

1.4 Key Growth Drivers

1.5 Key Challenges

1.6 Competitive Landscape Highlights

1.7 Pipeline & Innovation Snapshot

2. Disease & Epidemiology Analysis

2.1 Overview of TROP-2 Biology

2.1.1 Role of Trophoblast Cell Surface Antigen 2 (TROP-2) in Cancer

2.1.2 Expression Patterns Across Tumor Types

2.1.3 Mechanism of Oncogenic Activity

2.2 Target Indications Overview

2.2.1 Triple-Negative Breast Cancer (TNBC)

2.2.2 Hormone Receptor-Positive / HER2-Negative Breast Cancer

2.2.3 Non-Small Cell Lung Cancer (NSCLC)

2.2.4 Small Cell Lung Cancer (SCLC)

2.2.5 Urothelial Carcinoma

2.2.6 Other Solid Tumors (e.g., Endometrial, Pancreatic, Gastrointestinal)

2.3 Epidemiology by Indication

2.3.1 Global Cancer Burden Relevant to TROP-2 Expression

2.3.2 Incidence & Prevalence by Indication

2.3.3 Subtype-Level Epidemiology (e.g., TNBC vs HR+/HER2-)

2.3.4 Patient Eligibility for TROP-2 Targeted Therapies

2.4 Biomarker Landscape

2.4.1 TROP-2 Expression Testing

2.4.2 Companion Diagnostics Status

2.4.3 Biomarker-Driven Patient Stratification

3. Market Dynamics

3.1 Market Drivers

3.1.1 Rising Cancer Incidence

3.1.2 Increasing Adoption of Antibody-Drug Conjugates (ADCs)

3.1.3 Strong Clinical Outcomes of Approved TROP-2 Therapies

3.1.4 Expansion into Multiple Tumor Types

3.2 Market Restraints

3.2.1 High Cost of ADC Therapies

3.2.2 Safety & Toxicity Concerns (e.g., Neutropenia, Diarrhea)

3.2.3 Limited Biomarker Standardization

3.3 Market Opportunities

3.3.1 Expansion into Early-Line Therapy

3.3.2 Combination Therapies (Immunotherapy, Chemotherapy)

3.3.3 Emerging Markets Penetration

3.4 Market Challenges

3.4.1 Competitive Pressure from Other Targeted Therapies

3.4.2 Regulatory Complexity

3.4.3 Manufacturing Complexity of ADCs

4. Commercial & Market Access

4.1 Pricing Analysis

4.1.1 Pricing Benchmarks for TROP-2 Therapies

4.1.2 Regional Pricing Variability

4.2 Reimbursement Landscape

4.2.1 Public vs Private Payer Coverage

4.2.2 Reimbursement Challenges for ADCs

4.3 Market Access Strategies

4.3.1 Value-Based Pricing

4.3.2 Patient Assistance Programs

4.3.3 Market Entry Strategies

4.4 Distribution Channels

4.4.1 Hospital Pharmacies

4.4.2 Specialty Pharmacies

4.4.3 Oncology Centers

5. Innovation & Pipeline Landscape

5.1 Overview of TROP-2 Targeted Modalities

5.1.1 Antibody-Drug Conjugates (ADCs)

5.1.2 Monoclonal Antibodies

5.1.3 Bispecific Antibodies

5.1.4 Novel Modalities

5.2 Pipeline Analysis by Phase

5.2.1 Phase III Pipeline Candidates

5.2.2 Phase II Pipeline Candidates

5.2.3 Phase I Pipeline Candidates

5.3 Key Pipeline Drugs (Verified)

5.3.1 Sacituzumab Govitecan (Approved)

5.3.2 Datopotamab Deruxtecan (Late-Stage Pipeline)

5.3.3 Other Clinical Candidates (Only Verified Trials)

5.4 Mechanism of Action Analysis

5.4.1 Target Binding and Internalization

5.4.2 Payload Delivery Mechanisms

5.4.3 Linker Technologies

5.5 Clinical Trial Landscape

5.5.1 Ongoing Trials by Indication

5.5.2 Trial Design Trends

5.5.3 Key Endpoints and Outcomes

6. Treatment Landscape

6.1 Current Standard of Care by Indication

6.1.1 Breast Cancer Treatment Landscape

6.1.2 Lung Cancer Treatment Landscape

6.1.3 Urothelial Cancer Treatment Landscape

6.2 Positioning of TROP-2 Therapies

6.2.1 Line of Therapy (2L, 3L, etc.)

6.2.2 Comparison with Chemotherapy

6.2.3 Comparison with Other Targeted Therapies

6.3 Clinical Efficacy & Safety Profile

6.3.1 Efficacy Outcomes (ORR, PFS, OS)

6.3.2 Safety & Adverse Events

6.4 Treatment Guidelines

6.4.1 Inclusion in NCCN / ESMO Guidelines

6.4.2 Adoption Trends

7. TROP-2 Targeted Therapy MarketSize & Forecast

7.1 Global Market Size (Historical)

7.2 Market Forecast (2026-2031)

7.3 Growth Rate Analysis (CAGR)

7.4 Revenue Contribution by Key Drugs

7.5 Forecast by Indication

8. TROP-2 Targeted Therapy MarketSegmentation

8.1 by Type

8.1.1 Antibody-Drug Conjugates

8.1.2 Monoclonal Antibodies

8.1.3 Others

8.2 by Indication

8.2.1 Breast Cancer

8.2.2 Lung Cancer

8.2.3 Colorectal Cancer

8.2.4 Others

8.3 by End User

8.3.1 Hospitals

8.3.2 Specialty Clinics

8.3.3 Cancer Centers

9. Geographical Analysis (Regional Level)

9.1 North America

9.1.1 Market Size & Growth

9.1.2 Demand Drivers

9.1.3 Regulatory Overview

9.1.4 Competitive Intensity

9.2 Europe

9.2.1 Market Size & Growth

9.2.2 Demand Drivers

9.2.3 Regulatory Overview

9.2.4 Competitive Intensity

9.3 Asia-Pacific

9.3.1 Market Size & Growth

9.3.2 Demand Drivers

9.3.3 Regulatory Overview

9.3.4 Competitive Intensity

9.4 Latin America

9.4.1 Market Size & Growth

9.4.2 Demand Drivers

9.4.3 Regulatory Overview

9.4.4 Competitive Intensity

9.5 Middle East & Africa

9.5.1 Market Size & Growth

9.5.2 Demand Drivers

9.5.3 Regulatory Overview

9.5.4 Competitive Intensity

10. Key Countries Analysis

10.1 United States

10.2 Canada

10.3 Germany

10.4 United Kingdom

10.5 France

10.6 Italy

10.7 Spain

10.8 China

10.9 Japan

10.10 India

10.11 South Korea

10.12 Australia

10.13 Brazil

10.14 Mexico

10.15 Saudi Arabia

10.16 South Africa

11. Regulatory & Policy Landscape

11.1 United States (FDA)

11.1.1 Drug Approval Pathways for ADCs

11.1.2 Accelerated Approval Mechanisms

11.2 Europe (EMA)

11.2.1 Centralized Approval Process

11.2.2 Oncology-Specific Guidelines

11.3 Japan (PMDA)

11.3.1 Approval Framework

11.3.2 Oncology Drug Regulations

11.4 India (CDSCO)

11.4.1 Drug Approval Process

11.4.2 Import & Clinical Trial Regulations

11.5 China (NMPA)

11.5.1 Accelerated Oncology Approvals

11.5.2 Local Clinical Requirements

11.6 Global Regulatory Trends

11.6.1 ADC-Specific Guidelines

11.6.2 Real-World Evidence Integration

12. Competitive Landscape

12.1 Market Share Analysis

12.2 Competitive Positioning

12.3 Strategic Initiatives

12.3.1 Mergers & Acquisitions

12.3.2 Licensing & Collaborations

12.3.3 R&D Investments

12.4 SWOT Analysis

13. Company Profiles

13.1 Gilead Sciences, Inc.

13.1.1 Approved Product: Sacituzumab Govitecan (Trodelvy)

13.1.2 Key Indications

13.1.3 Pipeline & Clinical Development

13.2 AstraZeneca PLC

13.2.1 Pipeline Product: Datopotamab Deruxtecan

13.2.2 Key Indications

13.2.3 Clinical Trial Status

13.3 Daiichi Sankyo Company, Limited

13.3.1 Pipeline Product: Datopotamab Deruxtecan

13.3.2 Key Indications

13.3.3 Pipeline Details

13.4 Merck & Co., Inc.

13.4.1 Oncology Portfolio Relevance

13.4.2 Combination Trials with TROP-2 Therapies

13.5 F. Hoffmann-La Roche Ltd

13.5.1 Oncology Portfolio

13.5.2 Relevant Pipeline/Collaborations

13.6 Pfizer Inc.

13.6.1 Oncology Portfolio

13.6.2 Relevant Clinical Collaborations

13.7 BioNTech SE

13.7.1 Oncology Pipeline

13.7.2 Relevant Immunotherapy Combinations

13.8 BeiGene, Ltd.

13.8.1 Oncology Portfolio

13.8.2 Participation in Combination/Clinical Studies (Verified)

13.9 Sichuan Kelun Pharmaceutical

13.9.1 ADC Pipeline (TROP-2 Candidates if verified)

13.9.2 Clinical Development

13.10 Lepu Biopharma Co., Ltd.

13.10.1 TROP-2 ADC Pipeline (Verified Trials Only)

13.10.2 Development Status

14. Future Outlook

14.1 Market Evolution Trends

14.2 Emerging Technologies

14.3 Expansion into New Indications

14.4 Competitive Outlook

14.5 Long-Term Market Forecast

15. Methodology

15.1 Research Approach

15.2 Data Sources

15.3 Validation Techniques

15.4 Assumptions

15.5 Limitations

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/l5he4c

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.